down arrow

Turnstone Biologics Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US90042W1009
USD
0.35
0.00 (0.00%)

Aug 12

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

0.290.70
Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

How big is Turnstone Biologics Corp.?

22-Jun-2025

As of Jun 18, Turnstone Biologics Corp. has a market capitalization of 8.67 million and reported net sales of 0.00 million with a net profit of -63.01 million over the last four quarters. Shareholder's funds are at 31.47 million, and total assets amount to 40.14 million.

As of Jun 18, Turnstone Biologics Corp. has a market capitalization of 8.67 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -63.01 million during the same period.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 31.47 million and total assets amounting to 40.14 million.

Read More

What does Turnstone Biologics Corp. do?

22-Jun-2025

Turnstone Biologics Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $12 million and a market cap of $8.67 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -1.06.

Overview: <BR>Turnstone Biologics Corp. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -12 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 8.67 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.06 <BR>Return on Equity: -314.39% <BR>Price to Book: 0.43<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Turnstone Biologics Corp. technically bullish or bearish?

25-Jun-2025

As of April 30, 2025, the market trend is mildly bearish, influenced by mixed indicators such as a mildly bullish weekly MACD and bearish RSI, with daily moving averages also showing a bearish stance.

As of 30 April 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The weekly MACD is mildly bullish, but the RSI is bearish, indicating mixed signals. The Bollinger Bands show a mildly bullish trend on the weekly but are mildly bearish on the monthly. Daily moving averages are mildly bearish, while the Dow Theory indicates no trend on the weekly and bearish on the monthly. Overall, the strength of the bearish sentiment is tempered by some bullish indicators, particularly in the weekly timeframe.

Read More

Is Turnstone Biologics Corp. overvalued or undervalued?

25-Jun-2025

As of May 13, 2024, Turnstone Biologics Corp. is considered overvalued with a valuation grade of "does not qualify," reflecting significant financial distress, including a negative Return on Equity and a current price of $0.37, down from a 52-week high of $3.05.

As of 13 May 2024, the valuation grade for Turnstone Biologics Corp. has moved from risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is currently assessed as overvalued given its financial metrics, particularly with a Price to Book Value of 0.42 and an EV to EBITDA ratio of 0.22, which are low compared to industry standards. The Return on Capital Employed (ROCE) is extraordinarily high at 4781.82%, but this is misleading due to the negative Return on Equity (ROE) of -314.39%, reflecting the company's ongoing losses.<BR><BR>In comparison with peers, Turnstone Biologics Corp. has a negative P/E ratio of -0.138, while CARA Therapeutics, Inc. shows a more negative P/E of -6.235, and Kodiak Sciences, Inc. also does not qualify with a P/E of -0.9925. The company's current price of $0.37 is significantly down from its 52-week high of $3.05, and its year-to-date return of -25.88% starkly contrasts with the S&P 500's gain of 2.44% in the same period, reinforcing the view that the stock is overvalued in its current state.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 8 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.23

stock-summary
Return on Equity

-324.21%

stock-summary
Price to Book

0.56

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.26%
0%
6.26%
6 Months
-9.25%
0%
-9.25%
1 Year
-84.76%
0%
-84.76%
2 Years
-97.04%
0%
-97.04%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Turnstone Biologics Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-42.34%
EBIT to Interest (avg)
-68.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.06
Sales to Capital Employed (avg)
0.72
Tax Ratio
1.28%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
60.53%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.42
EV to EBIT
0.21
EV to EBITDA
0.22
EV to Capital Employed
10.04
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
4781.82%
ROE (Latest)
-314.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
RSI
Bearish
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 74.18% vs 0.93% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.70",
          "val2": "-21.60",
          "chgp": "73.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "-0.80",
          "chgp": "112.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.50",
          "val2": "-21.30",
          "chgp": "74.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -73.67% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -28.26% vs -79.22% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "19.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-71.50",
          "val2": "-55.30",
          "chgp": "-29.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.80",
          "val2": "-1.00",
          "chgp": "180.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-70.80",
          "val2": "-55.20",
          "chgp": "-28.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-3,011.10%",
          "chgp": "301.11%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.70
-21.60
73.61%
Interest
0.00
0.00
Exceptional Items
0.10
-0.80
112.50%
Consolidate Net Profit
-5.50
-21.30
74.18%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 74.18% vs 0.93% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
19.30
-100.00%
Operating Profit (PBDIT) excl Other Income
-71.50
-55.30
-29.29%
Interest
0.00
0.00
Exceptional Items
0.80
-1.00
180.00%
Consolidate Net Profit
-70.80
-55.20
-28.26%
Operating Profit Margin (Excl OI)
0.00%
-3,011.10%
301.11%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -73.67% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -28.26% vs -79.22% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Turnstone Biologics Corp. stock-summary
stock-summary
Turnstone Biologics Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."